{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:45:41Z","timestamp":1782211541934,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.msard.2022.104477","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:44:22Z","timestamp":1671795862000},"page":"104477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9204-3216","authenticated-orcid":false,"given":"Tim","family":"Spelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Horakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Onofrj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Grammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Csepany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavit","family":"Boz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Granella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Grand'Maison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104477_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103012","article-title":"The effectiveness of natalizumab vs fingolimod\u2013a comparison of international registry studies","volume":"53","author":"Andersen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104477_bib0010","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.0000000000002395","article-title":"Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study","volume":"86","author":"Barbin","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104477_bib0011","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/1352458516650736","article-title":"Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies","volume":"22","author":"Baroncini","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104477_bib0016","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Mult. Scler."},{"issue":"suppl 3","key":"10.1016\/j.msard.2022.104477_bib0007","first-page":"405","article-title":"The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a randomised, head-to-head phase 4 study","volume":"23","author":"Butzkueven","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104477_bib0006","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2022.104477_bib0015","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1177\/1352458514535282","article-title":"An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy","volume":"20","author":"Carruthers","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104477_bib0019","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.msard.2019.05.026","article-title":"The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study","volume":"33","author":"Curti","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"suppl 1","key":"10.1016\/j.msard.2022.104477_bib0001","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104477_bib0002","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.4103\/1673-5374.239432","article-title":"Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches","volume":"13","author":"Grand'Maison","year":"2018","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.msard.2022.104477_bib0017","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ane.12864","article-title":"Real-life clinical use of natalizumab and fingolimod in Austria","volume":"137","author":"Guger","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2022.104477_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176174","article-title":"The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: an observational study","volume":"12","author":"Izquierdo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2022.104477_bib0008","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1177\/1352458516653667","article-title":"Observational data: understanding the real MS world","volume":"22","author":"Kalincik","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104477_bib0012","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.24339","article-title":"Switch to natalizumab versus fingolimod in active relapsing remitting multiple sclerosis","volume":"77","author":"Kalincik","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.104477_bib0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104477_bib0018","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ane.12718","article-title":"A longitudinal real-life comparison study of natalizumab and fingolimod","volume":"136","author":"Lanzillo","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2022.104477_bib0021","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12874-022-01623-8","article-title":"Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis","volume":"22","author":"Lefort","year":"2022","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.msard.2022.104477_bib0013","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1352458518768433","article-title":"Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis","volume":"24","author":"Lorscheider","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104477_bib0004","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"S1","key":"10.1016\/j.msard.2022.104477_bib0023","first-page":"579","article-title":"The effects of natalizumab and fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis: a two-year comparative study","volume":"24","author":"Preziosa","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104477_bib0014","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00415-016-8343-5","article-title":"Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis","volume":"264","author":"Prosperini","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104477_bib0022","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40263-021-00860-7","article-title":"Natalizumab versus Fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts","volume":"35","author":"Sharmin","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2022.104477_bib0024","first-page":"1","article-title":"Efficacy of natalizumab and fingolimod in relapsing remitting multiple sclerosis in real world clinical setting","volume":"6","author":"Totaro","year":"2015","journal-title":"J. Neurol. Neurophysiol."},{"key":"10.1016\/j.msard.2022.104477_bib0009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis\u2014insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:06:10Z","timestamp":1761901570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822009816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":24,"alternative-id":["S2211034822009816"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104477","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104477"}}